Privium Fund Management B.V. Intra Cellular Therapies, Inc. Transaction History
Privium Fund Management B.V.
- $401 Million
- Q3 2024
A detailed history of Privium Fund Management B.V. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 117,983 shares of ITCI stock, worth $10 Million. This represents 2.15% of its overall portfolio holdings.
Number of Shares
117,983
Previous 117,983
-0.0%
Holding current value
$10 Million
Previous $8.08 Million
6.76%
% of portfolio
2.15%
Previous 2.28%
Shares
5 transactions
Others Institutions Holding ITCI
# of Institutions
378Shares Held
84.7MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$819 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$538 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$450 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$328 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$260 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $8.03B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...